BioSpace News Archive

Calyx today announced a strategic partnership with Ceretype Neuromedicine, Inc., whose novel functional MRI (fMRI) platform incorporates optimal image acquisition and advanced analytics to de-risk and accelerate the development of psychiatric and neurological therapies.

NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), a global leader in nanomedicines against viruses, announced today that it has executed a License Agreement with Karveer Meditech Pvt. Ltd., Kolhapur, India (“Karveer”).

SAB Biotherapeutics announced the appointment of Erick Lucera, CFA, a veteran of the biotechnology and medical device industry, with over thirty years of financial, operational and investment experience, to SAB’s Board of Directors, effective April 4, 2023.

Avid Bioservices, Inc. announced the completion of two expansions within the company’s mammalian cell facilities.

Repairon together with the University Medical Center Göttingen (UMG) and the University Medical Center Schleswig-Holstein (UKSH), Campus Lübeck, as well as the German Center for Cardiovascular Research (DZHK) today announced the completion of enrolment and follow-up of patients in the dose-finding cohort of the BioVAT-HF-DZHK20 Phase 1/2 trial.

BioMed X, an independent biomedical research institute, announces the start of its new research project - “New Strategies to Enhance the Immunogenicity of Tumors” - in collaboration with Merck.

The U.S. Army Medical Research and Development Command recently awarded MLM Biologics, Inc. almost $1.5 million to develop a device to prevent infection in battlefield wounds.

Cingulate Inc. announced it has completed the first cohort of its Phase 3 adult onset and duration trial of its lead candidate, CTx-1301, for attention deficit/hyperactivity disorder.

Lannett Company, Inc. shared a business update as it focuses on strategically positioning the Company to continue manufacturing and delivering safe, affordable, effective, life-enhancing generic pharmaceutical products for its valued patients and customers.

Oculis Holding AG announces that it will host a virtual conference call and webcast to present an overview of its late-stage pipeline and discuss expected near-term clinical milestones on Thursday, April 13 from 8:00am-9:00am ET / 13:00-14:00 BST / 14:00-15:00 CET.